Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2007

View Archived Issues

SKI-606 active in chronic myelogenous leukemia in phase I study

RHAMM/CD168-R3 peptide vaccine tested in AML, MDS and MM patients

Snapshots on MAb-based therapies for hematologic malignancies

Sanofi-aventis enters new option agreement for ImmunoGen's TAP technology

Bioequivalence study of ANX-530 cleared to begin

Targeting S1P3 may be useful to treat atherosclerosis

MedImmune to develop anti-ICOS monoclonal antibodies

LibiGel studied for female sexual dysfunction in phase III trial

Stiefel completes acquisition of Connetics

Partial responses in pancreatic cancer study of glufosfamide plus gemcitabine

Tumor responses in phase II study of CA4P, paclitaxel and carboplatin

Lorus Therapeutics reviews Q2 developments

Authorized generic Oxandrin launched by Watson

Oscient amends Factive license agreement with LG Life Sciences

Altana completes sale of pharma business to Nycomed

3M completes sale of pharma business in Americas

WelChol filed for treatment of type 2 diabetes

Novel antidiabetic agents claimed in recent patents

Enrollment open in phase II study of PX-12 for advanced pancreatic cancer

Stimuvax NSCLC phase III study opens for enrollment

Recent patents reveal development of novel agents for cardiovascular disorders

Novel agents for asthma, COPD, etc. described

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...